AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34519839 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD47 antibodies + IFN-α
Number of subjects: 0
Study 34519839 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRPαFc to block CD47
Number of subjects: 0
Study 34519964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 0
Study 34519964 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 34520127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent (IIV4) vaccine
Number of subjects: 239
Study 34520411 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week intervention to reduce sedentary time (SED) embedded in a pulmonary rehabilitation program (PRP)
Number of subjects: 21
Study 34520638 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antidepressant treatments
Number of subjects: 124
Study 34520638 — intervention group
Group type: COMPARATOR
Intervention: No systemic antidepressant treatments
Number of subjects: 124
Study 34520807 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cannabis users
Number of subjects: 70
Study 34520807 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 70
Study 34521057 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills for Improving Distress Intolerance (SIDI)
Number of subjects: 374
Study 34521057 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counseling
Number of subjects: 374
Study 34521057 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 374
Study 34521113 — intervention group
Group type: EXPERIMENTAL
Intervention: mAb CAEL-101 (11-1F4) administered as a single intravenous infusion with escalating doses from 0.5 mg/m2 to 500 mg/m2 in phase 1a and as 4 weekly infusions in phase 1b.
Number of subjects: 27
Study 34521113 — intervention group
Group type: EXPERIMENTAL
Intervention: mAb CAEL-101 (11-1F4)
Number of subjects: 27
Study 34521364 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) as a risk factor for IDH
Number of subjects: 8475
Study 34521364 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking as a risk factor for IDH
Number of subjects: 8475
Study 34521376 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sitting time
Number of subjects: 108
Study 34521376 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased prolonged sitting time (≥30 min)
Number of subjects: 108
Study 34521376 — intervention group
Group type: COMPARATOR
Intervention: Higher average sleep duration
Number of subjects: 108
Study 34521376 — intervention group
Group type: COMPARATOR
Intervention: Higher average sitting time
Number of subjects: 108
Study 34521376 — intervention group
Group type: COMPARATOR
Intervention: Higher average prolonged sitting time (≥30 min)
Number of subjects: 108
Study 34521479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac POCUS curriculum (pre-training online module and hands-on training with Butterfly iQ ultrasound)
Number of subjects: 6
Study 34521615 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and reminders through SMS text messaging and phone calls
Number of subjects: 264
Study 34521615 — intervention group
Group type: COMPARATOR
Intervention: Routine standard care
Number of subjects: 264
Study 34521615 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling (20-minute sessions with trained counselors and information leaflets)
Number of subjects: 264
Study 34521615 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder SMS text messaging and phone calls (SMS 3 days prior and phone call 1 day prior to scheduled visits)
Number of subjects: 264
Study 34521667 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 group (pregnant women who test positive for SARS-CoV-2)
Number of subjects: 86000
Study 34521667 — intervention group
Group type: COMPARATOR
Intervention: Non-infected group (screening group)
Number of subjects: 86000
Study 34521667 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based questionnaires based on validated instruments
Number of subjects: 86000
Study 34521667 — intervention group
Group type: EXPERIMENTAL
Intervention: Short- and long-term health outcomes from Swedish health registers
Number of subjects: 86000
Study 34521667 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 86000
Study 34521694 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for FH
Number of subjects: 336
Study 34521694 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of patients with polygenic hypercholesterolaemia
Number of subjects: 336
Study 34521694 — intervention group
Group type: COMPARATOR
Intervention: Comparison of cholesterol levels
Number of subjects: 336
Study 34521729 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating cell-free double-stranded DNA (ccf-dsDNA) levels in patients with rapid progression of IPF
Number of subjects: 0
Study 34521729 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating cell-free double-stranded DNA (ccf-dsDNA) levels in patients with slow progression of IPF
Number of subjects: 0
Study 34521729 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 34522028 — intervention group
Group type: EXPERIMENTAL
Intervention: Verlindamycin combined with all-trans-retinoic acid (ATRA)
Number of subjects: 0
Study 34522028 — intervention group
Group type: EXPERIMENTAL
Intervention: Verlindamycin
Number of subjects: 0
Study 34522028 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoid-based multimodal differentiation therapy
Number of subjects: 0
Study 34522093 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Morning Symptoms of COPD Instrument (EMSCI)
Number of subjects: 406
Study 34522093 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluating Respiratory Symptoms in COPD (E-RS™: COPD)
Number of subjects: 406
Study 34522093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime Symptoms of COPD Instrument (NiSCI)
Number of subjects: 406
Study 34522093 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported Physical Activity Level (PAL) through Exercise as Vital Sign (EVS) and Yale Physical Activity Survey (YPAS)
Number of subjects: 406
Study 34522093 — intervention group
Group type: COMPARATOR
Intervention: Physician-assessed Physical Activity Level (PAL)
Number of subjects: 406
Study 34522876 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-related cirrhosis
Number of subjects: 3533
Study 34522876 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-related cirrhosis
Number of subjects: 3533
Study 34522876 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aetiology cirrhosis
Number of subjects: 3533
Study 34523045 — intervention group
Group type: EXPERIMENTAL
Intervention: Management according to ophthalmic and systemic disease
Number of subjects: 9
Study 34523118 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 2314
Study 34523117 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in partnership interventions
Number of subjects: 16257
Study 34523117 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in partnership as part of a multi-component intervention
Number of subjects: 16257
Study 34523117 — intervention group
Group type: COMPARATOR
Intervention: Usual practice without partnership
Number of subjects: 16257
Study 34523117 — intervention group
Group type: COMPARATOR
Intervention: Multi-component intervention without partnership
Number of subjects: 16257
Study 34523717 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstruction
Number of subjects: 942
Study 34523717 — intervention group
Group type: COMPARATOR
Intervention: Billroth-I reconstruction
Number of subjects: 942
Study 34523725 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinks per drinking day (DPDD)
Number of subjects: 182
Study 34523725 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle frontal gyrus (MFG) thickness
Number of subjects: 182
Study 34523725 — intervention group
Group type: EXPERIMENTAL
Intervention: NfL
Number of subjects: 182
Study 34523725 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 182
Study 34523741 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated diastolic hypertension (IDH)
Number of subjects: 1605
Study 34524020 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34524092 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAVE SMS text messages
Number of subjects: 833
Study 34524092 — intervention group
Group type: COMPARATOR
Intervention: STEM SMS text messages
Number of subjects: 833
Study 34524092 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAVE SMS text messages after STEM intervention
Number of subjects: 833
Study 34524092 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messages for self-help
Number of subjects: 833
Study 34524092 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messages for helping friends/family
Number of subjects: 833
Study 34524220 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon α-2b (HD-IFN)
Number of subjects: 56
Study 34524263 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with FD
Number of subjects: 35
Study 34524263 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 35
Study 34524647 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin < 0.1 ng/mL
Number of subjects: 154
Study 34524647 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of positive blood culture bottles ≤ 2
Number of subjects: 154
Study 34524647 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-infection-related admission
Number of subjects: 154
Study 34524647 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of positive blood culture bottles ≤ 25%
Number of subjects: 154
Study 34525188 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression and eltrombopag (EPAG)
Number of subjects: 178
Study 34525286 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg vaccine
Number of subjects: 40
Study 34525286 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg vaccine
Number of subjects: 40
Study 34525286 — intervention group
Group type: EXPERIMENTAL
Intervention: Postvaccination serum
Number of subjects: 40
Study 34525286 — intervention group
Group type: COMPARATOR
Intervention: Baseline serum
Number of subjects: 40
Study 34525286 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg and 2 mg vaccines
Number of subjects: 40
Study 34525979 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive technology and telecare (ATT) devices
Number of subjects: 276
Study 34525979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking devices
Number of subjects: 276
Study 34525979 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday technology
Number of subjects: 276
Study 34525979 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to ATT for PwDs with severe dementia
Number of subjects: 276
Study 34526044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg d1, every 3 weeks, until disease progression, unacceptable toxicity, or up to 35 cycles) + SBRT (8 Gy × 3) + GM-CSF (125 μg/m)
Number of subjects: 20
Study 34526058 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based self-help telerehabilitation program assisted by EMG-driven WH-ENMS
Number of subjects: 11
Study 34526151 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavior Therapy (G-CBT) for 3 months
Number of subjects: 78
Study 34526151 — intervention group
Group type: COMPARATOR
Intervention: Individual Outpatient Treatment (IOT) for 3 months
Number of subjects: 78
Study 34526151 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavior Therapy (G-CBT)
Number of subjects: 78
Study 34526151 — intervention group
Group type: COMPARATOR
Intervention: Individual Outpatient Treatment (IOT)
Number of subjects: 78
Study 34526343 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional mobility assessments using Performance Oriented Mobility Assessment, Timed Up and Go, and Timed Up and Go dual task
Number of subjects: 350
Study 34526343 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly self-report of falls (including number and severity) confirmed through interviews
Number of subjects: 350
Study 34526343 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessments and neuroimaging (including molecular imaging using positron emission tomography and MRI)
Number of subjects: 350
Study 34526804 — intervention group
Group type: EXPERIMENTAL
Intervention: iota-carrageenan containing lozenge
Number of subjects: 31
Study 34527321 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients (n=38)
Number of subjects: 76
Study 34527321 — intervention group
Group type: COMPARATOR
Intervention: Non-COPD smokers (n=38)
Number of subjects: 76
Study 34527608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib followed by yttrium 90 glass microspheres
Number of subjects: 38
Study 34527608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 38
Study 34527608 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (sorafenib followed by yttrium 90 glass microspheres)
Number of subjects: 38
Study 34527722 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients (GOLD Grades I-IV)
Number of subjects: 2000
Study 34527722 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients (sub-cohort of 400)
Number of subjects: 2000
Study 34527722 — intervention group
Group type: COMPARATOR
Intervention: Never-smoker healthy controls
Number of subjects: 2000
Study 34527982 — intervention group
Group type: EXPERIMENTAL
Intervention: Active referral plus a small financial incentive (HK$300/US$38) after using cessation services within 3 months.
Number of subjects: 1093
Study 34527982 — intervention group
Group type: COMPARATOR
Intervention: General brief cessation advice (control group).
Number of subjects: 1093
Study 34528245 — intervention group
Group type: COMPARATOR
Intervention: Norethisterone (24 participants)
Number of subjects: 192
Study 34528245 — intervention group
Group type: COMPARATOR
Intervention: Progesterone 600 mg/day (168 participants)
Number of subjects: 192
Study 34528245 — intervention group
Group type: COMPARATOR
Intervention: Pooled progesterone RCTs
Number of subjects: 192
Study 34528308 — intervention group
Group type: COMPARATOR
Intervention: Dietary Inflammatory Index (DII)
Number of subjects: 415
Study 34528401 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34528591 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF
Number of subjects: 687
Study 34528591 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF + compression
Number of subjects: 687
Study 34528591 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF + compression + topical treatment
Number of subjects: 687
Study 34528591 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF + compression + topical treatment + endovasal laser coagulation
Number of subjects: 687
Study 34528591 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF + endovasal laser coagulation
Number of subjects: 687
Study 34528591 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF + compression + endovasal laser coagulation
Number of subjects: 687
Study 34528591 — intervention group
Group type: COMPARATOR
Intervention: Patients not receiving MPFF
Number of subjects: 687
Study 34528591 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving topical treatment
Number of subjects: 687
Study 34528591 — intervention group
Group type: COMPARATOR
Intervention: Patients not receiving compression therapy
Number of subjects: 687
Study 34528591 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving compression therapy
Number of subjects: 687
Study 34528763 — intervention group
Group type: EXPERIMENTAL
Intervention: Poziotinib 12 mg orally once daily for 28-day cycle
Number of subjects: 49
Study 34528857 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS 12
Number of subjects: 1129
Study 34528885 — intervention group
Group type: EXPERIMENTAL
Intervention: personalized communication using an mHealth app in addition to standard of care phone communication
Number of subjects: 400
Study 34528885 — intervention group
Group type: COMPARATOR
Intervention: standard of care communication only
Number of subjects: 400
Study 34528885 — intervention group
Group type: EXPERIMENTAL
Intervention: not available
Number of subjects: 400
Study 34529005 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET imaging scan (3 to 7 mCi)
Number of subjects: 764
Study 34529005 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET imaging scan
Number of subjects: 764
Study 34529078 — intervention group
Group type: EXPERIMENTAL
Intervention: PODCI
Number of subjects: 108
Study 34529078 — intervention group
Group type: EXPERIMENTAL
Intervention: PODCI expectations scale
Number of subjects: 108
Study 34529078 — intervention group
Group type: EXPERIMENTAL
Intervention: GMFM
Number of subjects: 108
Study 34529078 — intervention group
Group type: EXPERIMENTAL
Intervention: GMFCS
Number of subjects: 108
Study 34529182 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled prostacyclin analogues
Number of subjects: 0
Study 34529182 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled epoprostenol (VPCOVID [NCT04452669])
Number of subjects: 0
Study 34529182 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (ILOCOVID [NCT04445246])
Number of subjects: 0
Study 34529226 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term hydroxychloroquine (HCQ) intake
Number of subjects: 569
Study 34529226 — intervention group
Group type: COMPARATOR
Intervention: No antirheumatic drug intake
Number of subjects: 569
Study 34529255 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics initiated for presumed bacterial respiratory tract co-/superinfection
Number of subjects: 281
Study 34529255 — intervention group
Group type: EXPERIMENTAL
Intervention: Drivers of antibiotic prescribing
Number of subjects: 281
Study 34529313 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34529762 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (2 doses)
Number of subjects: 106
Study 34529762 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222 vaccine (1 dose)
Number of subjects: 106
Study 34529762 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (212 patients, 46% men; median age, 66 years)
Number of subjects: 106
Study 34529930 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) with dosing of 54 Gy in three fractions for peripheral lesions or 50 Gy in four fractions for central tumours (totaling 60 Gy).
Number of subjects: 80
Study 34529930 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 80
Study 34529930 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND)
Number of subjects: 80
Study 34529955 — intervention group
Group type: EXPERIMENTAL
Intervention: Indatuximab ravtansine plus lenalidomide
Number of subjects: 64
Study 34529955 — intervention group
Group type: EXPERIMENTAL
Intervention: Indatuximab ravtansine plus pomalidomide
Number of subjects: 64
Study 34529983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cockcroft-Gault creatinine clearance (C-G)
Number of subjects: 3985
Study 34530387 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-week therapeutic anticoagulation (enoxaparin or rivaroxaban)
Number of subjects: 241
Study 34530387 — intervention group
Group type: COMPARATOR
Intervention: Six-week anticoagulation (control group)
Number of subjects: 241
Study 34530728 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic drug prescriptions (PTDs)
Number of subjects: 696
Study 34530728 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic prescriptions
Number of subjects: 696
Study 34530728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedatives/hypnotics prescriptions
Number of subjects: 696
Study 34530733 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment initiation
Number of subjects: 111
Study 34530744 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for COVID-19 patients
Number of subjects: 0
Study 34530760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib 400 mg once daily and thalidomide 200 mg once daily until disease progression or intolerable toxicity
Number of subjects: 39
Study 34530760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib 400 mg once daily and thalidomide 200 mg once daily
Number of subjects: 39
Study 34530793 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation treatment for lower limb fractures
Number of subjects: 204
Study 34530834 — intervention group
Group type: EXPERIMENTAL
Intervention: JUUL-brand electronic cigarettes for 6 weeks
Number of subjects: 114
Study 34530933 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care CPG implementation facilitators
Number of subjects: 35
Study 34530933 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care CPG implementation barriers
Number of subjects: 35
Study 34531196 — intervention group
Group type: EXPERIMENTAL
Intervention: NICE NG51 CPG
Number of subjects: 555
Study 34531196 — intervention group
Group type: EXPERIMENTAL
Intervention: NICE NG143 CPG
Number of subjects: 555
Study 34531196 — intervention group
Group type: EXPERIMENTAL
Intervention: BSAC CPG
Number of subjects: 555
Study 34531244 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnl-GT-β-cell failure
Number of subjects: 486
Study 34531244 — intervention group
Group type: COMPARATOR
Intervention: Abnl-GT-IR
Number of subjects: 486
Study 34531244 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of Abnl-GT
Number of subjects: 486
Study 34531249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg on day 1 and carboplatin AUC 2 on days 8 and 15 of a 3-week cycle until progression
Number of subjects: 29
Study 34531249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with carboplatin
Number of subjects: 29
Study 34531242 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic glucose response curve
Number of subjects: 3108
Study 34531242 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic glucose response curve
Number of subjects: 3108
Study 34531242 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous rise glucose response curve
Number of subjects: 3108